Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| TVTX | Travere Therapeutics | $23.05 | -$11.05 | -32.41% | 8.9M | $3.1B | $12.91$42.13 |
| ATRA | Atara Biotherapeutics | $4.64 | -$1.24 | -21.09% | 21.9K | $42M | $4.63$19.15 |
| ELAB | Pmgc | $4.36 | -$0.91 | -17.27% | 366.9K | $2.7M | $3.54$398.86 |
| AKAN | Akanda | $2.18 | -$0.45 | -17.11% | 616K | $1.9M | $2.06$46.45 |
| RGC | Regencell Bioscience | $37.30 | -$6.82 | -15.45% | 522.6K | $22B | $0.09$83.60 |
| AHT | Ashford Hospitality Trust | $3.66 | -$0.66 | -15.34% | 177.7K | $28M | $2.90$10.35 |
| EMAT | Evolution Metals & Technologies | $14.01 | -$2.44 | -14.83% | 36.3K | $47M | $7.05$24.37 |
| FIGG | Themes ETF Trust - Leverage Shares 2x Long Fig Daily ETF | $3.69 | -$0.63 | -14.57% | 668.5K | - | $3.62$16.34 |
| LGND | Ligand Pharmaceuticals | $179.17 | -$27.64 | -13.36% | 308.7K | $4.1B | $93.58$212.49 |
| PDDL | GraniteShares ETF Trust - GraniteShares 2x Long Pdd Daily ETF | $27.01 | -$3.70 | -12.06% | 43.2K | - | $24.19$43.73 |
Related Articles
Featured Article
A Nearly 1,100% Gain: Here's the 1 Key Reason Why This Forgotten Tech Stock Crushed the S&P 500
Scott Levine|Dec 5, 2025
After years of struggling with one key metric, this tech company has found its way back onto investors' buy lists.
This Stock Soared 9,800% in 2025. Here's 1 Key Reason Why Investors Are Piling In (Spoiler: It's Regencell Bioscience Holdings (RGC) Stock)
Selena Maranjian|Nov 24, 2025
Is the stock likely to keep surging? The answer seems pretty clear.
This Fitness Tech Stock Has Crushed Apple's 2025 Gains -- 1 Reason Why
Lyle Daly|Oct 19, 2025
The Amazfit brand has helped Zepp Health bounce back in a big way after years of negative returns.
Advertisement
Could an FDA Approval Send This Stock Flying?
David Jagielski, CPA|Mar 1, 2023
Is now the time to load up on this struggling stock?
2 Real Estate Stocks to Avoid Like the Plague
Liz Brumer|Feb 18, 2022
These two stocks are headed in the wrong direction, and the risks far outweigh any potential reward.
Ligand's Revenue Soars in Q1 Thanks to Gilead's COVID Drug
Keith Speights|May 4, 2021
The drugmaker is also looking for its highest sales ever in 2021 in large part because of remdesivir.
3 Signs the Ligand Short Squeeze Is Over
Jason Hawthorne|Apr 22, 2021
The Reddit crowd wasn't the only reason short-sellers got burned betting against this pharmaceutical company.
Forget Gamestop! This Highly Shorted Stock Is a Strong Buy Now
Jason Hawthorne|Feb 9, 2021
The unusual biotech could be a bitter pill for short sellers to swallow.
Short-Sellers Have These 3 ETFs in Their Sights
Dan Caplinger|Feb 3, 2021
Should investors watch for a squeeze?
2 Steps to Biotech Success: Good Data, Then Raise Capital
Brian Orelli, PhD|Dec 23, 2020
Companies that don't do the second step won't last long in this industry.
![Biotech_Stocks_Step_1_Good_Data,_Step_2_Raise_Capital[1]](https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F605702%2Fbiotech_stocks_step_1_good_data_step_2_raise_capital1.jpg&w=384&op=resize)